Navigation Links
Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Date:9/6/2007

rmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

* Coreg(R) is a registered trademark of GlaxoSmithKline.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Anuj Baveja

RF Binder Partners Inc.

(212) 994-7552


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
11. SRL Ranbaxy offers quicker bird flu diagnostic test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...ey Spears has been warned to stop drinking. Accord...d that she might have done irreparable damage to ...lor John Sundahl had told her: "If you fall off th...you will live. If you don't want to get sober for ...
...hat humans distant ancestors won the battle agains... left the human species vulnerable to HIV today. ...esent century and one of the most researched one s...d about its origin. Many researchers believe that ...
...shop owner was sentenced to two years probation fo...rced the evacuation of a rooming house beside his ...nts of sexual assault and one count of sexual expl...victims testified that Claro caressed and groped t...
...ermany have died of the feared H5N1 strain of bird...of a total of 14 birds tested positive for the H5N...itute institute said. A health official, Katja Gue...t tests carried out by the same institute confirme...
Other Medicine News:Health News:Ancient Ancestors Might Have Had a Clue to HIV 2Health News:Two Year Probation for Cobra Owner Helder Claro 2Health News:Six Cases of H5N1 Bird Flu Confirmed in Germany 2
(Date:10/13/2008)...ene(R)-F Surface Treatment Maximizes,Endothelializ...or Long-Term,Dual Antiplatelet Therapy, WASHINGTO...at today,s,"Innovative Devices and Futuristic Ther...r Cardiovascular Therapeutics (TCT) scientific,sym...oundation, presented,12-month follow-up data from ...
(Date:10/13/2008)...wswire/ -- Facet Solutions, Inc. today,announced t...from its US,IDE Pilot Study. The results show a 78...res, and an 80% reduction in Visual Analog Scores ...dent & CEO for Facet Solutions,added, "We are ver... not,only demonstrate significant pain relief but ...
(Date:10/10/2008)...f., Oct. 10 /-,XTENT, Inc. ...present,long-term follow-up data from the CUSTOM I...iovascular Research Foundation,s (CRF) twentieth a...CT) meeting in Washington, DC.,The CUSTOM clinical...igate,the safety and efficacy of the Custom NX(R) ...
(Date:10/10/2008)...ire-FirstCall/ -- Boston Scientific,Corporation (N...mpany,s major,events and press announcements at th...ieth annual Transcatheter Cardiovascular Therapeut...tober 12 to 17 in Washington, D.C., Boston Scient...,efficacy data on its TAXUS(R) Express2(TM) and se...
Breaking Medicine Technology:12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6Stabilizing cancer fighting p53 can also shield a metastasis promoter 20062 1Stabilizing cancer fighting p53 can also shield a metastasis promoter 20062 2GlaxoSmithKline Announces 24500 000 in Fellowships at Stanford Graduate School of Business 20058 1GlaxoSmithKline Announces 24500 000 in Fellowships at Stanford Graduate School of Business 20058 2GlaxoSmithKline Announces 24500 000 in Fellowships at Stanford Graduate School of Business 20058 3Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 20054 1Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 20054 2ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 1ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 2ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 3ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 4ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 5ATHENA Clinical Results with Dronedarone 28Multaq 28R 29 29 Highlighted at the World Cardiology Congress 2174 6
... IL -- CytImmune, a clinical stage nanomedicine co...tion of,multifunctional, tumor-targeted therapies ...ican Society of Clinical Oncology (ASCO),Annual me...f a,Phase 1 Clinical Trial of CYT-6901," announced...te conducted and CytImmune Sciences,sponsored Phas...
...ix products from Pharmion,s pipeline provide suppo...ding promising Phase III,data on use of Thalidomid...1, 2007 /PRNewswire-FirstCall/ -- Pharmion,Corpora... studies,investigating the company,s marketed and ...t the American Society of Clinical,Oncology,s (ASC...
Other Medicine Technology:CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago 2CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7
...e; is a 1-step, hand-held, point-of-care device fo...lites in human urine. The TOX/See device can dete... 3 to 8 minutes and requires only a few drops of u...ed to maximize convenience and ease of use. TOX/Se...
...e; is a 1-step, hand-held, point-of-care device fo...lites in human urine. The TOX/See device can dete... 3 to 8 minutes and requires only a few drops of u...ed to maximize convenience and ease of use. TOX/Se...
...e; is a 1-step, hand-held, point-of-care device fo...lites in human urine. The TOX/See device can dete... 3 to 8 minutes and requires only a few drops of u...ed to maximize convenience and ease of use. TOX/Se...
Sugar-Chex Linearity is a whole blood formulation designed to cover the linear reportable range of the most popular glucose meters. The product meets CAP recommendations of using a control matrix tha
Medicine Products: